| Literature DB >> 33789637 |
Norhan K Abd El-Aziz1, Ahmed M Ammar2, El-Sayed Y M El-Naenaeey2, Hend M El Damaty3, Asmaa A Elazazy4, Ahmed A Hefny5, Asmaa Shaker6, Ibrahim E Eldesoukey7.
Abstract
BACKGROUND: Streptococcus agalactiae (S. agalactiae) is a contagious pathogen of bovine mastitis. It has financial implications for the dairy cattle industry in certain areas of the world. Since antimicrobial resistance increases in dairy farms, natural antimicrobials from herbal origins and nanoparticles have been given more attention as an alternative therapy. Hence, this study reported the antimicrobial and antibiofilm potentials of cinnamon oil, silver nanoparticles (AgNPs), and their combination against multidrug-resistant (MDR) S. agalactiae recovered from clinical bovine mastitis in Egypt.Entities:
Keywords: Antibiofilm potential; Antimicrobial activity; Cinnamon oil; Mastitis; Silver nanoparticles
Year: 2021 PMID: 33789637 PMCID: PMC8010958 DOI: 10.1186/s12917-021-02842-9
Source DB: PubMed Journal: BMC Vet Res ISSN: 1746-6148 Impact factor: 2.741
Antimicrobial susceptibilities of S. agalactiae isolated from clinical bovine mastitis
| Isolate code No. | Antimicrobial agents | MAR index | ||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P | AX | AMC | CX | CRO | CFP | CL | FEP | IPM | S | DA | CIP | TE | E | SXT | ||
| R | R | S | R | R | R | R | R | S | R | R | S | R | R | R | 0.86 | |
| R | R | I | R | R | R | R | I | S | R | R | S | R | R | R | 0.79 | |
| R | R | R | R | R | R | R | R | S | R | R | S | R | R | S | 0.86 | |
| R | R | R | R | R | R | R | S | S | R | R | S | R | R | R | 0.86 | |
| R | R | R | R | R | R | R | R | S | R | R | S | R | R | S | 0.86 | |
| R | R | R | R | R | R | R | S | S | R | R | S | R | R | R | 0.86 | |
| R | R | S | R | R | R | R | S | S | R | R | S | R | R | S | 0.71 | |
| R | R | R | R | R | R | R | S | S | R | R | S | R | R | S | 0.79 | |
| R | R | R | R | R | R | R | S | S | R | R | S | R | R | S | 0.79 | |
| R | R | S | R | R | R | R | S | S | R | R | S | R | R | S | 0.71 | |
| R | R | R | R | R | R | R | S | S | R | R | S | R | R | S | 0.79 | |
| R | R | I | R | R | R | R | R | S | R | R | S | R | R | S | 0.79 | |
| R | R | R | R | R | R | R | R | S | R | R | S | R | R | S | 0.86 | |
| R | R | S | R | R | R | R | R | S | R | R | S | R | R | S | 0.79 | |
| 14 (100.00) | 14 (100.00) | 8 (57.14) | 14 (100.00) | 14 (100.00) | 14 (100.00) | 14 (100.00) | 6 (42.86) | 0 (0.00) | 14 (100.00) | 14 (100.00) | 0 (0.00) | 14 (100.00) | 14 (100.00) | 4 (28.57) | NE | |
| 0.07 | 0.07 | 0.04 | 0.07 | 0.07 | 0.07 | 0.07 | 0.03 | 0.00 | 0.07 | 0.07 | 0.00 | 0.07 | 0.07 | 0.02 | NE | |
P penicillin G, AX amoxicillin, AMC amoxicillin-clavulanic acid, CX cloxacillin, CRO ceftriaxone, CFP cefoperazone, CL cephalexin, FEP cefepime, IPM imipenem, S streptomycin, DA clindamycin, CIP ciprofloxacin, TE tetracycline, E erythromycin, SXT trimethoprim-sulfamethoxazole, MAR multiple antibiotic resistance, R resistant, I intermediate, S sensitive, NE not estimated
Antimicrobial resistance patterns, biofilm forming ability and virulence genes expression levels in S. agalactiae isolated from clinical bovine mastitis
| Isolate No | Antimicrobial resistance pattern | Biofilm formation | Virulence genes relative expressionb | Accession No. | ||||||
|---|---|---|---|---|---|---|---|---|---|---|
| OD570a | Degree | |||||||||
| 1 | P, AX, CX, CRO, CL, FEP, S, DA, TE, E, CFP | 0.498 | Weak | 1.16 | 1.09 | – | 1.20 | – | 1.50 | MW133069 |
| 2 | P, AX, CX, CRO, CL, FEP, S, DA, TE, E, AMC | 0.492 | Weak | 1.15 | 1.12 | – | 1.21 | – | 1.53 | MW133070 |
| 3 | P, AX, CX, CRO, CL, FEP, S, DA, TE, E, AMC | 1.121 | Strong | 1.10 | 1.04 | – | 1.14 | – | 1.42 | MW133071 |
| 4 | P, AX, CX, CRO, CL, FEP, S, DA, TE, E, CFP, SXT, AMC | 0.514 | Weak | 1.14 | 1.07 | – | 1.16 | – | 1.43 | MW133072 |
| 5 | P, AX, CX, CRO, CL, FEP, S, DA, TE, E, CFP, SXT | 0.508 | Weak | 1.13 | 1.04 | – | 1.15 | – | 1.45 | MW133073 |
| 6 | P, AX, CX, CRO, CL, FEP, S, DA, TE, E, AMC | 0.484 | Weak | 1.16 | 0.97 | – | 1.15 | – | 1.46 | MW133074 |
| 7 | P, AX, CX, CRO, CL, FEP, S, DA, TE, E, AMC | 0.812 | Moderate | 1.13 | 1.05 | – | 1.23 | – | 1.47 | MW133075 |
| 8 | P, AX, CX, CRO, CL, FEP, S, DA, TE, E, CFP | 0.494 | Weak | 1.37 | 1.05 | – | 1.44 | – | 1.81 | MW133076 |
| 9 | P, AX, CX, CRO, CL, FEP, S, DA, TE, E, AMC | 0.492 | Weak | 1.14 | 1.13 | – | 1.22 | – | 1.53 | MW133077 |
| 10 | P, AX, CX, CRO, CL, FEP, S, DA, TE, E, AMC | 1.118 | Strong | 1.11 | 1.04 | – | 1.04 | – | 1.43 | MW133078 |
| 11 | P, AX, CX, CRO, CL, FEP, S, DA, TE, E, CFP, SXT, AMC | 0.434 | Weak | 1.14 | 1.07 | – | 1.14 | – | 1.43 | MW133079 |
| 12 | P, AX, CX, CRO, CL, FEP, S, DA, TE, E, CFP, SXT | 0.528 | Weak | 1.13 | 1.04 | – | 1.16 | – | 1.46 | MW133080 |
| 13 | P, AX, CX, CRO, CL, FEP, S, DA, TE, E | 0.470 | Weak | 1.14 | 1.03 | – | 1.06 | – | 1.45 | MW133081 |
| 14 | P, AX, CX, CRO, CL, FEP, S, DA, TE, E | 0.820 | Moderate | 1.14 | 1.06 | – | 1.15 | – | 1.48 | MW133082 |
P penicillin G, AX amoxicillin, CX cloxacillin, CRO ceftriaxone, CL cephalexin, FEP cefepime, S streptomycin, DA clindamycin, TE tetracycline, E erythromycin, CFP cefoperazone, AMC amoxicillin-clavulanic acid, SXT trimethoprim-sulfamethoxazole
a The optical density (OD) was measured at 570 nm using the ELISA reader (stat fax 2100, USA)
b The expression level of each virulence gene was calculated as the ratio of intensity of the target gene to the internal control gene (gyrA)
In vitro antibacterial activities of cinnamon oil, silver nanoparticles and their combination against S. agalactiae isolated from clinical bovine mastitis
| Isolate No. | Zone diameters for the agar well diffusion method (mm)* | MIC (μg/mL)** | ΣFIC | Interactive category | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Cinnamon oil (%) | Silver nanoparticles (%) | Cinnamon oil | Silver nanoparticles | Cinnamon oil/ Silver nanoparticles | |||||||
| 100 | 50 | 25 | 100 | 50 | 25 | ||||||
| 1 | 38 | 29 | 20 | 31 | 24 | 18 | 0.063 | 8 | 0.00012/0.125 | 0.02 | Synergistic |
| 2 | 40 | 31 | 23 | 29 | 22 | 17 | 0.004 | 8 | 0.0005/0.250 | 0.16 | Synergistic |
| 3 | 40 | 30 | 22 | 30 | 23 | 16 | 0.016 | 8 | 0.0005/0.250 | 0.06 | Synergistic |
| 4 | 39 | 28 | 19 | 28 | 25 | 19 | 0.016 | 16 | 0.002/0.125 | 0.13 | Synergistic |
| 5 | 36 | 27 | 18 | 30 | 21 | 17 | 0.008 | 16 | 0.002/0.125 | 0.26 | Synergistic |
| 6 | 36 | 26 | 18 | 28 | 21 | 15 | 0.031 | 16 | 0.0005/0.250 | 0.03 | Synergistic |
| 7 | 40 | 33 | 21 | 29 | 23 | 18 | 0.063 | 8 | 0.0005/0.250 | 0.04 | Synergistic |
| 8 | 36 | 28 | 21 | 30 | 21 | 17 | 0.016 | 8 | 0.002/0.125 | 0.14 | Synergistic |
| 9 | 40 | 32 | 23 | 30 | 22 | 16 | 0.004 | 8 | 0.0005/0.250 | 0.16 | Synergistic |
| 10 | 40 | 30 | 22 | 28 | 22 | 16 | 0.063 | 16 | 0.00012/0.125 | 0.01 | Synergistic |
| 11 | 39 | 30 | 21 | 31 | 23 | 18 | 0.016 | 8 | 0.002/0.125 | 0.02 | Synergistic |
| 12 | 36 | 28 | 19 | 28 | 25 | 19 | 0.016 | 16 | 0.0005/0.250 | 0.05 | Synergistic |
| 13 | 36 | 26 | 18 | 29 | 22 | 17 | 0.031 | 8 | 0.0005/0.250 | 0.05 | Synergistic |
| 14 | 40 | 34 | 23 | 27 | 20 | 15 | 0.008 | 16 | 0.002/0.125 | 0.3 | Synergistic |
| Mean ± SE | 38.29 ± 0.50 | 29.43 ± 0.66 | 20.57 ± 0.51 | 29.14 ± 0.33 | 22.43 ± 0.40 | 17.00 ± 0.35 | 0.01± 0.01 | 11.43± 1.10 | 0.0010 ± 0.0002 | – | – |
MIC minimum inhibitory concentration, ΣFIC fractional inhibitory concentration index; SE, standard error
* Means ± standard errors of the inhibition zones` diameters for different concentrations (25, 50 and 100%) of cinnamon oil or silver nanoparticles carrying different superscripts are highly significant (P < 0.0001)
** Means ± standard errors of the MIC values of cinnamon oil or silver nanoparticles (serial dilutions were done for each antibacterial agent starting from 1024 μg/mL and downwards) and their combination carrying different superscripts are highly significant (P < 0.0001)
Fig. 1Killing kinetics of the MIC levels of cinnamon oil, silver nanoparticles, and their combination on the viability of S. agalactiae isolates (time-kill curve). Bacterial survival was reported at 0, 1, 2, 4, 6, 8, 10, 12, and 24 h incubation time points by the colony forming unit (CFU) assay. The data are expressed as the means ± SE of three separate experiments, each containing three replicates
Fig. 2Increased percentages of biofilm inhibition (X-axis) correspond to a serial concentration (Y-axis) of cinnamon oil, silver nanoparticles (a), and both substances (b). Each data point refers to the average of biofilm inhibition % at the respective concentration, and the error bar refers to the standard error mean
Fig. 3Effects of cinnamon oil, silver nanoparticles (a), and their combination (b) on the biofilm formation of S. agalactiae. For each substance, the number of isolates exhibiting certain MBIC50 is shown +/− standard error mean. Stars indicate a significant difference among the MBIC50 of cinnamon oil and silver nanoparticles
Fig. 4Comparative measurement of the transcription (cDNA abundance) of biofilm associated genes (pilA and pilB) and their regulator (rogB) in strong biofilm producing S. agalactia isolates (codes No. 3 and 10; Table 2) after treatment with MBIC50 values of cinnamon oil (2, 4 μg/mL), silver nanoparticles (32, 64 μg/mL) and their combination (1/2, 8/16 μg/mL), respectively. The data are presented as fold changes in gene expressions normalized to an endogenous housekeeping gene (gyrA) and relative to the untreated control isolate, which was assigned a value of 1.Error bars indicate standard deviations. Double asterisks (**) represent the means significantly different from control untreated isolate (P < 0.05). Pearson’s correlation indicates the positive correlations of rogB transcript levels and biofilm biosynthesis genes at r ≥ 0.3